755 related articles for article (PubMed ID: 33687906)
1. Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease.
Iqubal A; Iqubal MK; Fazal SA; Pottoo FH; Haque SE
Curr Mol Pharmacol; 2022; 15(1):23-50. PubMed ID: 33687906
[TBL] [Abstract][Full Text] [Related]
2. Current Quest in Natural Bioactive Compounds for Alzheimer's Disease: Multi-Targeted-Designed-Ligand Based Approach with Preclinical and Clinical Based Evidence.
Iqubal A; Rahman SO; Ahmed M; Bansal P; Haider MR; Iqubal MK; Najmi AK; Pottoo FH; Haque SE
Curr Drug Targets; 2021; 22(6):685-720. PubMed ID: 33302832
[TBL] [Abstract][Full Text] [Related]
3. Current Strategies and Novel Drug Approaches for Alzheimer Disease.
Ghai R; Nagarajan K; Arora M; Grover P; Ali N; Kapoor G
CNS Neurol Disord Drug Targets; 2020; 19(9):676-690. PubMed ID: 32679025
[TBL] [Abstract][Full Text] [Related]
4. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A
J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs.
Thakral S; Yadav A; Singh V; Kumar M; Kumar P; Narang R; Sudhakar K; Verma A; Khalilullah H; Jaremko M; Emwas AH
Ageing Res Rev; 2023 Jul; 88():101960. PubMed ID: 37224884
[TBL] [Abstract][Full Text] [Related]
6. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
Morató X; Pytel V; Jofresa S; Ruiz A; Boada M
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012569
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
8. [Anti-dementia drugs for Alzheimer disease in present and future].
Nabeshima T; Noda Y; Kamei H
Nihon Yakurigaku Zasshi; 2002 Nov; 120(1):24P-29P. PubMed ID: 12491771
[TBL] [Abstract][Full Text] [Related]
9. Nutraceuticals-based therapeutic approach: recent advances to combat pathogenesis of Alzheimer's disease.
Talebi M; Kakouri E; Talebi M; Tarantilis PA; Farkhondeh T; İlgün S; Pourbagher-Shahri AM; Samarghandian S
Expert Rev Neurother; 2021 Jun; 21(6):625-642. PubMed ID: 33910446
[No Abstract] [Full Text] [Related]
10. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic approaches of nutraceuticals in the prevention of Alzheimer's disease.
Pandey SN; Singh G; Semwal BC; Gupta G; Alharbi KS; Almalki WH; Albratty M; Najmi A; Meraya AM
J Food Biochem; 2022 Dec; 46(12):e14426. PubMed ID: 36169224
[TBL] [Abstract][Full Text] [Related]
12. [Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
Shimohama S
Rinsho Shinkeigaku; 2013; 53(11):1036-8. PubMed ID: 24291871
[TBL] [Abstract][Full Text] [Related]
13. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
[TBL] [Abstract][Full Text] [Related]
14. Phytochemicals-based Therapeutics against Alzheimer's Disease: An Update.
Ayaz M; Nawaz A; Naz F; Ullah F; Sadiq A; Islam ZU
Curr Top Med Chem; 2022; 22(22):1811-1820. PubMed ID: 36029077
[TBL] [Abstract][Full Text] [Related]
15. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
Salomone S; Caraci F; Leggio GM; Fedotova J; Drago F
Br J Clin Pharmacol; 2012 Apr; 73(4):504-17. PubMed ID: 22035455
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation.
Kanubaddi KR; Yang SH; Wu LW; Lee CH; Weng CF
Int J Nanomedicine; 2018; 13():8473-8485. PubMed ID: 30587972
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Noetzli M; Eap CB
Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
[TBL] [Abstract][Full Text] [Related]
19. (-)-Oleocanthal Nutraceuticals for Alzheimer's Disease Amyloid Pathology: Novel Oral Formulations, Therapeutic, and Molecular Insights in 5xFAD Transgenic Mice Model.
Tajmim A; Cuevas-Ocampo AK; Siddique AB; Qusa MH; King JA; Abdelwahed KS; Sonju JJ; El Sayed KA
Nutrients; 2021 May; 13(5):. PubMed ID: 34069842
[TBL] [Abstract][Full Text] [Related]
20. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Van Dam D; Abramowski D; Staufenbiel M; De Deyn PP
Psychopharmacology (Berl); 2005 Jun; 180(1):177-90. PubMed ID: 15654502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
